ナルコレプシー2型患者を対象としたTAK-861の研究

基本情報

NCT ID

NCT05687916

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

71

治験依頼者名

Takeda

概要

The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT). The study will enroll approximately 60 participants and they will be randomly assigned to 3 groups (20 per group) to take one of two different doses of TAK-861 or a placebo. All the participants will receive the treatment for 8 weeks. Participants will be asked to complete some questionnaires during the study. This trial will be conducted in North America, Europe, and Asia Pacific.

対象疾患

介入

依頼者（Sponsor）

実施施設 (11)